Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7362457 | 0.72 | — | — | |
| SCHEMBL3225542 | 0.70 | SMN1; SMN2 (0.43) | KDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL21031966 | 0.67 | LMNA (0.44) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL3706662 | 0.65 | TSHR (0.58) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL15660796 | 0.65 | — | — | |
| SCHEMBL30832410 | 0.64 | LMNA (0.38) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL3079790 | 0.64 | SMN1; SMN2 (0.46) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL24846875 | 0.62 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL426628 | 0.62 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL7436133 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660085-B1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1660475-B1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | disclosed |
| US-7279575-B2 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2007-10-09 | — | — | US | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660475-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005014572-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | KDM4E 803/4885LMNA 3902/4885CYP2C19 1346/4885 |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | TYMP, DTYMK, DCK | KDM4E 959/4885LMNA 4408/4885CYP2C19 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.